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not clear whether these multiple alleles
represent separate translocation events
or aneusomy of a previously translo-
cated chromosome. The latter possibility
is favored, given that: (1) the partner
status (7q32.3 or other) was identical in
the allele pairs from each case; (2) two
of the three cases demonstrated aneu-
ploidy; and (3) 6p25.3 translocations
appear to be an early event during
lymphomagenesis, based on our con-
stant finding of this translocation in
initial biopsies from patients with
multiple tumor specimens over time
(AL Feldman, unpublished observation).
In addition to the lack of a normal
copy of the 6p25.3 allele, multiple
copies of the translocations could
have implications on the partner
locus. For example, we previously
reported overexpression of microRNAs
(especially MIR29B1) that reside
near the 7q32.3 breakpoint in ALK-
negative ALCLs with t(6;7)(p25.3;q32.3)
(Feldman et al., 2009).
In summary, we present three cases of
pcALCL with biallelic rearrangements of
6p25.3 and no intact copies of the
DUSP22–IRF4 locus. These cases indi-
cate one mechanism by which both
copies of the DUSP22 gene can be
disrupted or deleted in T-cell lympho-
mas, and provide further evidence that
DUSP22 may represent a tumor-
suppressor gene.
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TO THE EDITOR
Loxosceles spiders are a genus of ara-
chnids, whose bites cause necrotizing
skin lesions. They are distributed world-
wide in temperate and tropical regions.
In Brazil, approximately 10,000 cases
of Loxosceles spider bites are reported
annually. L. intermedia, L. gaucho,
and L. laeta are prevalent in most of
the southern states of Brazil, whereas
L. similis has been described mainly in
the state of Minas Gerais. L. reclusa
and L. deserta cause the majority of
accidents in North America. The
venoms of these species all have similar
biochemical and pharmacological pro-
files (Barbaro et al., 2005; Silvestre
et al., 2005; Chatzaki et al., 2012).
The envenomation, described as
loxoscelism, is characterized by pain,
local edema, and erythema, followed
by dermonecrosis that require weeks to
heal. The genesis of loxoscelism is
attributed to a family of sphingo-
myelinase D enzymes, also known as
Accepted article preview online 25 January 2013
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Loxtox proteins (Kalapothakis et al.,
2007). Since the discovery that these
enzymes have several phospholipid
substrates besides sphingomyelin, they
have been named phospholipase D
(PLD; Van Meeteren et al., 2004; Lee
and Lynch, 2005; Chaim et al., 2011).
Furthermore, the complex pathophysio-
logical mechanisms underlying cuta-
neous loxoscelism have been discussed.
Dragulev et al. (2007) showed that
L. reclusa PLD upregulated the expres-
sion of proinflammatory cytokines/chemo-
kines in human fibroblasts. The authors
proposed that ceramide-1-phosphate
formed by the hydrolysis of plasma
membrane sphingomyelin is responsible
for this effect. This speculation was
challenged by Van Meeteren et al.
(2007), who hypothesized that lysophos-
phatidic acid (LPA), a product of lyso-
phosphatidylcholine (LPC) hydrolysis,
is the likely trigger for the observed
response, rather than ceramide-1-
phosphate. LPC is an abundant plasma
component (approximately 150mM) and
serves as a genuine physiological
substrate for PLD (Van Meeteren et al.,
2004).
On the basis of this intriguing discus-
sion, we investigated the role of LPA
receptors in the release of cytokines/
chemokines and in cell death caused
by treatment of fibroblasts with L. similis
venom (LsV). For comparison, we also
used recombinant L. intermedia dermo-
necrotic protein 1 (recLiD1), a well-
described toxin (Kalapothakis et al.,
2002; Felicori et al., 2006). PLD
activity was detected for LsV and
recLiD1 (data not shown).
HFF-1 human fibroblast cells (BCRJ/
UFRJ, Rio de Janeiro, Brazil) were main-
tained in DMEM with 15% serum.
Before treatment, cells were maintained
in serum-free DMEM for 4 hours. Subse-
quently, the medium was changed, and
the cells were treated for 12 hours with
10mg ml1 LsV, 10mg ml1 recLiD1
(both pre-incubated for 1 hour at 37 1C
with 10mM LPC), 15mM LPA, 10mM LPC,
or 10 ng ml1 tumor necrosis factor-a in
serum-free DMEM. Untreated cells
served as negative controls. Treatments
were performed in the absence or pre-
sence of 15mM Ki16425, an LPA recep-
tor (LPA1/LPA3) antagonist, which was
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Figure 1. The lysophosphatidic acid (LPA) receptor antagonist Ki16425 decreases the release of cytokines/chemokines induced by stimulation of HFF-1 cells
with L. similis venom (LsV) or recombinant L. intermedia dermonecrotic protein 1 (recLiD1). LsV and recLiD1 were pre-incubated for 1 hour at 37 1C with 10mM
1-oleoyl-lysophosphatidylcholine (LPC; complexed to 5 mg ml1 fatty acid-free albumin). HFF-1 cells were then incubated for 12 hours with 10mM LPC,
10mg ml1 LsV or recLiD1, in the absence or presence of 15mM Ki16425. Untreated cells served as negative controls. Graphs show the levels (pgml1) of IL-6 (a),
IL-8 (b), CXCL1 (c), and CXCL2 (d) in conditioned medium from cell cultures. Values represent the mean±SEM of triplicate determinations from three independent
experiments. #Po0.05 compared with LPC control group; *Po0.05 compared with experimental LsV/recLiD1 groups (two-way analysis of variance, Bonferroni
post-hoc test).
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added 30 minutes before the addition of
each agent. After treatment, aliquots of
conditioned medium from cell cultures
were collected for analysis of cytokine/
chemokine levels using ELISA kits for
human IL-6, IL-8, IL-1b, RANTES (Life
Technologies, Rockville, MD), CXCL1
(Abnova, Taipei, Taiwan), and CXCL2
(Immuno-Biological, Gunma, Japan).
AlamarBlue assay (Life Technologies)
was performed to confirm cell viability
after stimulation, with 10mg ml1 LsV
or recLiD1 for 12 hours (data not
shown).
Exposure of HFF-1 to LsV or recLiD1
stimulated the release of IL-6, IL-8,
CXCL1, and CXCL2. Cells produced
lower levels of mediators after LPC
stimulation (Figure 1). Loxosceles
venoms have been shown to promote
the release of inflammatory mediators in
different experimental models (Barbaro
et al., 2010). However, the participation
of LPA receptors in this venom
inflammatory response has not yet
been investigated. In our assays,
Ki16425 significantly inhibited the
production of cytokines/chemokines by
HFF-1 after treatment with LsV and
recLiD1 (Figure 1). It is known that
HFF-1 cells express LPA1, LPA2, and
LPA3 receptors (Zhang et al., 1999).
Control cells treated with LPA
exhibited results similar to those of
cells treated with LsV or recLiD1, and
tumor necrosis factor-a induced
secretion of the mediators tested (data
not shown).
These data indicate that LPA, formed
by PLD activity of LsV and recLiD1,
induces liberation of cytokines/chemo-
kines via LPA receptor-mediated path-
ways. LPA is a bioactive phospholipid
that is involved in many cellular func-
tions, including cytokine/chemokine
secretion (Fang et al., 2004). As Loxo-
sceles PLD has several phospholipid
targets, it is necessary to acknowledge
that other mediators may also
participate in these inflammatory effects.
We next investigated whether LPA
receptors were involved in cell death
induced by longer incubation with LsV.
Previous results from AlamarBlue assays
revealed that cell survival decreased
after 24–48 hours of incubation with
LsV (data not shown). Therefore, HFF-1
monolayers were stimulated with
10mg ml1 LsV, 10mg ml1 recLiD1
(both pre-incubated with 10mM LPC),
15mM LPA, or 10mM LPC in 15% serum
DMEM for 48 hours. Ki16425 was added
as previously described. Untreated cells
served as negative controls. After incuba-
tion, cells were trypsinized and washed
with phosphate-buffered saline. The cells
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Figure 2. Lysophosphatidic acid (LPA) receptors are not involved in apoptotic cell death of human
fibroblast and endothelial cells treated with L. similis venom (LsV) or recombinant L. intermedia
dermonecrotic protein 1 (recLiD1). LsV and recLiD1 were pre-incubated for 1 hour at 37 1C with 10mM 1-
oleoyl-lysophosphatidylcholine (LPC; complexed to 5 mg ml 1 fatty acid-free albumin). Human umbilical
vein endothelial cells (HUVECs) and HFF-1 cells were then incubated for 48 hours with 10mg ml1 LsV or
recLiD1. Untreated cells served as negative controls. Treatments were performed in the absence or
presence of 15mM Ki16425. Graphs show the percentage of HFF-1 cells (a) and HUVECs (b) labeled with
Annexin V-Cy3 and/or 7-aminoactinomycin d (7-AAD). Values represent the mean±SEM of triplicate
determinations from three independent experiments. Note: cells in early apoptosis are Annexin V-Cy3-
positive (black bars).
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were then incubated in Apoptosis/Necro-
sis Detection Kit buffer containing 1% v/
v 7-AAD and Annexin V-Cy3 (Enzo
LifeSciences, Farmingdale, NY), and sub-
jected to flow cytometry.
Treatment with LsV or recLiD1
caused HFF-1 cell death after 48 hours,
primarily due to apoptosis, which was
not inhibited by Ki16425 (Figure 2a).
The lack of inhibition was expected, as
treatment with LPA did not cause cell
death. Control LPC did not injure cells
either (data not shown). As LPA can
act as a cell survival or apoptotic
factor, dependent upon the cell type
(Ye et al., 2002), we performed the
same procedures using human
umbilical vein endothelial cells, which
yielded similar results (Figure 2b).
Thus, we did not find that LPA parti-
cipates in apoptosis induced by LsV or
recLiD1 in fibroblast and endothelial
cells in vitro. These cells are known
sites of Loxosceles venom interaction.
Our results support the idea that PLD
initiates the effects of Loxosceles venom
through stimulation of acute inflamma-
tory responses.
In conclusion, LPA receptors are in-
volved in the release of proinflammatory
cytokines/chemokines provoked by LsV
and recLiD1. The present work contri-
butes to the open discussion regarding
the participation of LPA in the patho-
physiology of cutaneous loxoscelism
and paves the way for investigation of
new therapeutic strategies.
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Mutations in ERBB4 May Have a Minor Role in Melanoma
Pathogenesis
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TO THE EDITOR
In the recent past, an increasing amount
of evidence has indicated that several
alterations to the complex molecular
machinery that provides checks and
balances in normal melanocytes may
be involved in the pathogenesis of mela-
noma (Palmieri et al., 2009; Tsao et al.,
2012). The different molecular pathways
associated with melanomagenesis seem
to correspond to specific subsets of
melanoma patients, with distinguished
biological and clinical behavior of the
disease. In the era, just begun, of
innovative targeted therapies for the
treatment of melanoma (Ascierto et al.,
2012; Flaherty et al., 2012), identi-
fication of such different subsets of
melanoma patients is becoming
mandatory.Accepted article preview online 22 January 2013
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